Table 3.
Failure of empirical treatment for non-ESBL- and ESBL-producing E. coli UTI (adjusted for age, sex and resistance)
| Age and sex | 14-day HR (99% CI) | 30-day HR (99% CI) | ||
|---|---|---|---|---|
| non-ESBL | ESBL | non-ESBL | ESBL | |
| Pivmecillinam | Ref. | Ref. | Ref. | Ref. |
| Ciprofloxacin | 0.93 (0.75–1.16) |
3.73 (2.39–5.83)II |
0.84 (0.69–1.01) |
2.89 (1.89–4.42)II |
| Nitrofurantoin | 0.93 (0.76–1.14) |
0.54 (0.24–1.19) |
1.07 (0.91–1.25) |
0.81 (0.47–1.38) |
| Aminopenicillinsa | 1.99 (1.60–2.49)II |
2.23 (0.97–5.12) |
1.81 (1.49–2.21)II |
1.89 (0.89–4.02) |
| Sulfamethizole | 1.71 (1.59–1.83)II |
2.22 (1.66–2.95)II |
1.51 (1.42–1.60)II |
1.69 (1.30–2.20)II |
| Trimethoprim | 1.25 (1.02–1.53)I |
2.21 (1.06–4.60)I |
1.16 (0.97–1.38) |
1.71 (0.87–3.37) |
| Age, sex and resistance | ||||
| Pivmecillinam | Ref. | Ref. | Ref. | Ref. |
| Ciprofloxacin | 0.64 (0.50–0.82)II |
1.43 (0.83–2.44) |
0.63 (0.51–0.78)II |
1.32 (0.79–2.19) |
| Nitrofurantoin | 0.95 (0.77–1.17) |
0.47 (0.19–1.19) |
1.09 (0.92–1.28) |
0.83 (0.47–1.47) |
| Aminopenicillinsa | 1.02 (0.80–1.30) |
0.68 (0.26–1.77) |
1.02 (0.82–1.27) |
0.63 (0.26–1.55) |
| Sulfamethizole | 1.01 (0.93–1.10) |
1.22 (0.88–1.71) |
1.00 (0.94–1.08) |
1.05 (0.78–1.41) |
| Trimethoprim | 0.96 (0.78–1.18) |
1.29 (0.61–2.73) |
0.95 (0.80–1.14) |
1.13 (0.57–2.25) |
Notes: aAmoxicillin or pivampicillin. Ip<0.01, IIp<0.001.